secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001157523-23-000779
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus Q1 net loss $70.9M; botensilimab combo shows 63% 12-month OS in colorectal cancer
--------------------------------------------------------------------------------

- Revenue $22.9M, net loss $70.9M ($0.22 EPS) vs loss $50.6M ($0.19 EPS) year ago.
- Cash & investments $189.2M at March 31; raised $13.6M in ATM sales post-quarter.
- Botensilimab/balstilimab: 63% 12-month OS in non-MSI-H CRC (vs 25% SOC); 33% ORR in platinum-resistant ovarian cancer.
- FDA granted Fast Track for botensilimab/balstilimab in non-MSI-H/dMMR mCRC without active liver metastases.
- Distributed ~5M MiNK shares (NASDAQ: INKT) as dividend to AGEN shareholders on May 1, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000115752323000779/0001157523-23-000779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000115752323000779/a53395899.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer